PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 1, 1996Journal of Clinical Oncology62 citations

Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.

View Full Paper
SLSteven E. Lipshultz

Key Points

Key points are not available for this paper at this time.

Abstract

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.2.328 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8636739 Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. S E LipshultzxS E LipshultzSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.2.328 First Page PDF © 1996 by American Society of Clinical Oncology

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Steven E. Lipshultz (1996) studied this question.

synapsesocial.com/papers/6a7d248845db7d096f6e4847https://doi.org/10.1200/jco.1996.14.2.328
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dexrazoxane as a Cardioprotectant in Children Receiving Anthracyclines2010 · 29 citations
  2. 2Dexrazoxane for anthracycline cardiotoxicity prevention in pediatric and AYA cancers: Systematic review and meta-analysis.2026
  3. 3Dexrazoxane2014 · 15 citations
  4. 4Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients2005 · 18 citations
  5. 5Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients2012 · 20 citations